Clinical Trials

A clinical trial is a research study that patients may volunteer to participate in to advance new medical treatments. Clinical trials are designed to explore the safety and efficacy of treatments not yet available to everyone. Patients who are interested in becoming participants are screened prior to registering into a trial to determine eligibility. Trials have very specific criteria. For example, the trial may be designed for patients who have not already received a certain type of chemotherapy drug. If you have received that drug, you may not be able to participate in that particular trial.

The screening process often includes signing an informed consent, getting blood work done to evaluate the function of vital organs prior to treatment, and having CT scans. Based on these tests, it will be determined whether or not the new treatment is recommended and/or available to you. Those who enter into a trial always have the option to leave at any time and under any circumstances.

We believe that clinical trials provide our patients with more options in the treatment of hematology and oncology. Clinical trials are essential in providing new treatments and medications before they become available to the public. It is through clinical trials that the FDA approves these new therapies.

If you are interested or have questions, please ask your doctor or fill out the form below for more information.

Available clinical trials offered at Cancer Care of North Florida include:

Biodesix-BDX-00145: Site 103

An Observational Study Assessing the Clinical Effectiveness of the VeriStrat® Test and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer. (Liquid blood draw; before first treatment, progression, or change of treatment).

Kartos-KRT-232-113: Site 1058

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis.

Caris-TCBIO-001-0710: Site 0247

Biospecimens will be collected from donors by study team members at participating sites. A limited set of information related to the specimen and health status of the subject will be collected initially. Additional data may be collected annually for up to 5 years or until the subject’s death, whichever occurs first. Confirmed stage III or IV disease of any solid tumor type. (Liquid blood draw; Also, Caris pathology consent form ordered & faxed).

Keynote/Novocure-EF-36/Keynote B36: Site 10-718

A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer.

The MT Group-MTG-022: Site 236

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients. (Umbrella Study: Liquid blood draws.)

MT1410-A

A pilot study looking at next-generation epigenomic and big data approaches to diagnose and treat cancer patient. Will apply patterns of DNA hydroxymethylation and other epigenomic characteristics to provide new biologic and clinical information, going beyond the standard approach. (Only 1 blood draw).

MT0291

Biomarkers Study in Fresh/Frozen blood, Fresh/Frozen tissue, and FFPE of Patients scheduled to receive I.O. Therapy. (We do not collect any Frozen tissue only blood; we do not have access to the tissue).

This study requires multiple collections:

1) Pre-Therapy (Visit 1)
2) 4-8 weeks after start of therapy (Visit 2)
3) 3-4 months after start of therapy (Visit 3)
4) 6 months after the start of therapy (Visit 4)
5) 12 months after the start of therapy (Visit 5)
6) 18 months after the start of therapy (Visit 6)
7) At Progression

BMS NIVO CA209234: Site 1907

Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice – Syneos Health Project No.: 15BMS-0164 (1 Patient still on treatment; monitored monthly. No longer enrolling patients as of December 31st 2021. Will continue to monitor patient until they have progression; passes; or has reaction to treatment).

Why Choose Us?

  • Highly trained, collaborative oncology specialists all currently taking new patients
  • Consultation appointments scheduled within 3-5 days of referral and in some cases same-day appointments available
  • One-stop campus for comprehensive diagnositics and treatment for many types of cancer including radiation, chemotherapy infusion, lab draws and imaging services
  • Onsite infusion center offers comfortable, home-like setting
  • In-office lab testing
  • In-office medication dispensary
  • Open, immediate access to outpatient symptom management
  • 24-hour physician coverage
  • COPI-certified clinical trials
  • We accept most insurance plans including Medicare, Medicaid, and VA